Oppenheimer Reiterates Outperform Rating for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer in a note issued to investors on Friday,Benzinga reports. They currently have a $41.00 price target on the stock, down from their previous price target of $42.00. Oppenheimer’s target price points to a potential upside of 176.47% from the stock’s current price.

PHAR has been the subject of several other reports. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. HC Wainwright set a $37.00 price objective on Pharming Group and gave the stock a “buy” rating in a research report on Thursday. Finally, Zacks Research downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Pharming Group Stock Down 2.0%

NASDAQ:PHAR traded down $0.31 during trading hours on Friday, reaching $14.83. The company’s stock had a trading volume of 20,598 shares, compared to its average volume of 29,159. The stock has a 50 day moving average price of $17.26 and a two-hundred day moving average price of $16.05. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The company has a market capitalization of $1.04 billion, a P/E ratio of -1,481.52 and a beta of 0.04. Pharming Group has a 12 month low of $7.50 and a 12 month high of $21.34.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.08). Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The company had revenue of $106.50 million for the quarter, compared to the consensus estimate of $111.76 million. Equities analysts predict that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its holdings in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the period. Millennium Management LLC acquired a new stake in shares of Pharming Group during the 4th quarter worth approximately $360,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group during the 4th quarter valued at approximately $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group during the 2nd quarter valued at approximately $32,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $37 price target on PHAR, and projects FY2026 EPS of $0.35 (supportive sentiment from a well-known boutique healthcare analyst).
• Neutral Sentiment: Pharming reaffirmed its 2026 guidance and reported Q4 revenue of $106.5M — the guidance confirmation reduces downside risk even though revenue was slightly below consensus. Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance
• Neutral Sentiment: Earnings call transcript and company materials (press release and slide deck) are available — useful for investors digging into margin drivers, product uptake and 2026 guidance details. Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript Press Release
• Neutral Sentiment: Coverage pieces previewing the quarter and noting increased pipeline investment highlight that R&D spend and pipeline execution are near-term focus areas; these can swing sentiment depending on upcoming milestones. Pharming earnings on deck as pipeline investment ramps up
• Negative Sentiment: Q4 EPS of $0.07 missed the consensus $0.15 estimate and revenue ($106.5M) came in below the ~$111.8M consensus — an earnings miss that likely pressured the share price. Pharming Q4 earnings report
• Negative Sentiment: HC Wainwright trimmed its FY2026 EPS forecast from $0.49 to $0.35 — a downward revision that signals tempered near-term profitability expectations even though the firm retained a Buy stance.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.